CN111413504B - Standard comparison card for assisting interpretation of KI67 proliferation index - Google Patents
Standard comparison card for assisting interpretation of KI67 proliferation index Download PDFInfo
- Publication number
- CN111413504B CN111413504B CN202010262409.6A CN202010262409A CN111413504B CN 111413504 B CN111413504 B CN 111413504B CN 202010262409 A CN202010262409 A CN 202010262409A CN 111413504 B CN111413504 B CN 111413504B
- Authority
- CN
- China
- Prior art keywords
- hot spot
- proliferation index
- proliferation
- spot region
- comparison card
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6875—Nucleoproteins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57415—Specifically defined cancers of breast
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57496—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving intracellular compounds
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06T—IMAGE DATA PROCESSING OR GENERATION, IN GENERAL
- G06T7/00—Image analysis
- G06T7/0002—Inspection of images, e.g. flaw detection
- G06T7/0012—Biomedical image inspection
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06T—IMAGE DATA PROCESSING OR GENERATION, IN GENERAL
- G06T2207/00—Indexing scheme for image analysis or image enhancement
- G06T2207/30—Subject of image; Context of image processing
- G06T2207/30004—Biomedical image processing
- G06T2207/30068—Mammography; Breast
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06T—IMAGE DATA PROCESSING OR GENERATION, IN GENERAL
- G06T2207/00—Indexing scheme for image analysis or image enhancement
- G06T2207/30—Subject of image; Context of image processing
- G06T2207/30004—Biomedical image processing
- G06T2207/30096—Tumor; Lesion
Abstract
The invention relates to the field of immunohistochemical detection, and particularly discloses a preparation method of a standard comparison card for assisting interpretation of KI67 proliferation indexes, which comprises the following steps: 1) the full-automatic digital section scanning system scans KI67 tumor tissue sections subjected to immunohistochemical staining to obtain image data; 2) selecting a hot spot region in the image data, and judging the proportion of KI67 positive cells in the hot spot region to tumor cells in the hot spot region by using a computer, wherein the proportion is a KI67 proliferation index; 3) a picture of 1 or more hot spot regions of known KI67 proliferation index was taken. The standard of the method is better than the accuracy of a comparison card, is not easily influenced by the seniority of a doctor, and can assist the doctor to stably judge the proliferation index of KI 67.
Description
Technical Field
The present invention relates to the field of immunohistochemical detection.
Background
KI67 is a non-histone cortical protein, expressed in the cell cycle G1, S, G2 and M phase nuclei, but not in the G0 phase (cytostatic). Therefore, the proportion of cells expressing KI67 detected in tumor cells (also called the "KI 67 proliferation index") can reflect the proportion of dividing cells in tumor cells, and is often used to judge the malignancy of tumors, with KI67 proliferation index being higher, and generally higher.
The KI67 proliferation index has become a predictive and prognostic factor for Breast Cancer (BC). Gallen's guidelines, hyperproliferative KI67 is one of the features of increased risk of recurrence of Estrogen Receptor (ER) positive HER2 negative BC, indirectly supporting the value of these patients to incorporate chemotherapy in endocrine therapy. The san gallon consensus in 2013 suggested a KI67 index cutoff of 20% in ER positive HER2 negative BC, while the threshold accepted by most groups in 2015 was in the range of 20% -29%.
At present, a standardized method for KI67 interpretation is lacked, so that KI67 interpretation results obtained by different observers or laboratories are greatly different, and the reliability of the results is not guaranteed. Therefore, the american society for clinical oncology (ASC0) tumor marker guidelines and the international KI67 working group do not suggest the routine use of KI67 as a prognostic assessment for newly diagnosed BC patients.
In order to reduce subjective errors caused by differences between observers and laboratories and improve the reliability of the KI67 interpretation result, a method for assisting K167 standardized interpretation needs to be established.
Disclosure of Invention
The invention aims to provide a standard comparison card for assisting in interpretation of the proliferation index of the breast cancer K167.
The technical scheme of the invention comprises the following steps:
a preparation method of a standard comparison card for assisting in interpreting K167 proliferation indexes comprises the following steps:
1) the full-automatic digital section scanning system scans KI67 tumor tissue sections subjected to immunohistochemical staining to obtain image data;
2) selecting a hot spot region in the image data, and judging the proportion of KI67 positive cells in the hot spot region to tumor cells in the hot spot region by using a computer, wherein the proportion is a KI67 proliferation index;
3) intercepting pictures of 1 or more hot spot areas with known KI67 proliferation indexes;
the hot spot region refers to an image region with 1% -99% of KI67 positive cells in the image data.
The preparation method, wherein the tumor in the step 1) is breast cancer.
According to the preparation method, at least 1 area of the hot spot areas intercepted in the step 3) has the KI67 proliferation index in the range of 20-29%.
As in the previous preparation method, in the hot spot region intercepted in step 3), the corresponding proliferation index of KI67 includes at least 1 of 5%, 10%, 15%, 20%, 30%, 40%, 50%, 60%, 70%, 80%.
According to the preparation method, the proliferation indexes of KI67 in the hot spot regions intercepted in the step 3) are 5%, 10%, 15%, 20%, 30%, 40%, 50%, 60%, 70% and 80%.
The preparation method comprises the step of printing the picture obtained in the step 3).
The standard comparison card for assisting in interpreting the proliferation index of KI67 is prepared by the method.
The invention has the following beneficial effects:
compared with a conventional interpretation method, the standard of the invention has higher accuracy and higher repeatability, and is not easily influenced by subjective factors.
Compared with the standard of displaying the KI67 interpretation standard by the picture mode for the card, the standard of the invention has the advantages of low cost and convenient use.
Obviously, many modifications, substitutions, and variations are possible in light of the above teachings of the invention, without departing from the basic technical spirit of the invention, as defined by the following claims.
The present invention will be described in further detail with reference to the following examples. This should not be understood as limiting the scope of the above-described subject matter of the present invention to the following examples. All the technologies realized based on the above contents of the present invention belong to the scope of the present invention.
Drawings
FIG. 1 is a scatter plot of the KI67 proliferation index from baseline and first, second, and third visits by each physician.
FIG. 2 is a scatter diagram of KI67 proliferation indexes obtained by each physician in the first, second and third interpretation, which are compared two by two.
Detailed Description
Example 1 methods of making and using a standard comparison card of the present invention
KI67 immunohistochemically stained breast cancer tumor sections were scanned using a PRECICE 600 series model fully automated digital section scanning system and converted to whole slide image data. Selecting the area with the highest KI67 positive cell proportion as a 'hot spot' area, judging the proportion of KI67 positive cells in the hot spot area in the tumor cells in the hot spot area as a KI67 proliferation index by a computer, selecting the areas with the KI67 proliferation indexes of 5%, 10%, 15%, 20%, 30%, 40%, 50%, 60%, 70% and 80%, respectively, intercepting the area of the picture, and performing color printing to obtain the picture.
When the kit is used, only the KI67 immunohistochemical stained section of the breast cancer to be detected is compared with each standard comparison card, the closest standard comparison card is searched, and the KI67 proliferation index of the sample to be detected is about the KI67 proliferation index corresponding to the closest standard comparison card.
Example 2 methods of making and using a standard comparison card of the present invention
KI67 immunohistochemically stained breast cancer tumor sections were scanned using a PRECICE 600 series model fully automated digital section scanning system and converted to whole slide image data. Selecting the area with the highest KI67 positive cell proportion as a 'hot spot' area, judging the proportion of KI67 positive cells in the hot spot area in the tumor cells in the hot spot area as a KI67 proliferation index by a computer, selecting the areas with the KI67 proliferation indexes of 15%, 20%, 30%, 50% and 80%, intercepting the area of the picture, and carrying out color printing to obtain 10 different standard cards.
When the kit is used, only the breast cancer K167 immunohistochemical staining section to be detected is compared with each standard comparison card, the closest standard comparison card is searched, and the KI67 proliferation index of the sample to be detected is about the KI67 proliferation index corresponding to the closest standard comparison card.
The proliferation index of KI67 corresponding to the standard comparison card of the invention is not limited to the proliferation index of KI67 listed in the examples, and the proliferation index can be set according to actual conditions and actual requirements.
The advantageous effects of the present invention will be further described below in the form of experimental examples.
Experimental example 1 verification of the Effect of the Standard ratio of the present invention on the card
The purpose of this experimental example was to compare the size of the effect of the human interpreter using the conventional interpretation method (method 1), the method using the conventional standard comparison card (method 2) and the method using the standard comparison card of the present invention (method 3).
The method 1 comprises the following steps: in daily work of a pathologist, no auxiliary tool is provided, a hot spot region in a KI67 immunohistochemical staining glass slide is selected under a microscope, and the KI67 positive cell ratio is manually read, namely the KI67 proliferation index of the breast cancer is obtained;
the method 2 is based on the embodiment 1, and the KI67 proliferation index interpreted by a computer is changed into manual counting, and specifically comprises the following steps:
scanning KI67 immunohistochemically stained slides using a PRECICE 600 series model fully automated digital slide scanning system and converting to whole slide image data, selecting a hot spot region in KI67 immunohistochemically stained slides,manual countingObtaining the proportion of KI67 positive cells in each 500 cells, namely KI67 proliferation index, and performing color printing on 5%, 10%, 15%, 20%, 30%, 40%, 50%, 60%, 70% and 80% of regional screenshots of the KI67 proliferation index to obtain 10 conventional standard comparison cards. When the kit is used, the KI67 immunohistochemical stained section of the breast cancer to be detected is compared with each standard comparison card, the closest standard comparison card is searched, and the KI67 proliferation index of the sample to be detected is about the KI67 proliferation index corresponding to the closest standard comparison card.
The procedure 3 is as in example 1.
1. Method of producing a composite material
1) 100 breast invasive cancer specimens are selected and subjected to KI67 immunohistochemical staining, and are interpreted by 5 different pathologists with different annual capital, from doctor A to doctor E, which participate in the work for 5 years, 3 years, 2 years, 1 year and less than 1 year respectively.
The 100 specimens are interpreted by each physician 3 times, the first time using the method 1, the second time using the method 2 and the third time using the method 3; the time interval of the first, second and third interpretation is 1 week.
2) All tumor cells on each section were counted manually on a computer image and the number of positive cells/total number of tumor cells was calculated as baseline.
3) The interpreted KI67 proliferation index is analyzed by using a computer program SPSS (social science statistics software package) version 16, the consistency of each interpretation result of each pathologist and a baseline and the consistency of pairwise comparison of each judgment result of each pathologist are judged, and then the kappa values are calculated for 3 times respectively.
The Kappa value is explained as follows: if < 0, there is no consistency at all; when the concentration is 0-0.20, the consistency is poor; when the concentration is 0.21-0.40, the consistency is general; consistency is moderate when 0.41-0.60 is needed; when the concentration is 0.61-0.8, the consistency is stronger; 0.80-1.00 of strong consistency.
2. Results
As shown in FIG. 1, the linear correlation between KI67 values and the baseline gradually increased in the first, second and third interpretation passes of each physician, and also indicated that the interpretation accuracy increased.
As shown in Table 1, the kappa value was highest, i.e., more consistent, from baseline for the third pass of the three interpretations.
TABLE 1 agreement of triplicate calls with baseline (kappa number)
As shown in Table 2 and FIG. 2, the results of the pairwise comparisons by each physician showed significantly higher consistency in the third interpretation compared to the remaining two.
TABLE 2 Kappa number for pairwise doctor comparisons
In conclusion, the standard of the method is better than the accuracy of the verification card, is not easily influenced by the seniority of the doctor, and can assist the doctor in stably judging the proliferation index of the KI 67.
Claims (6)
1. A preparation method of a standard comparison card for assisting in interpreting a proliferation index of KI67 comprises the following steps:
1) the full-automatic digital section scanning system scans KI67 tumor tissue sections subjected to immunohistochemical staining to obtain image data;
2) selecting a hot spot region in the image data, and judging the proportion of KI67 positive cells in the hot spot region to tumor cells in the hot spot region by using a computer, wherein the proportion is a KI67 proliferation index;
3) intercepting pictures of 1 or more hot spot areas with known KI67 proliferation indexes; at least 1 of the intercepted hotspot regions had KI67 proliferation indices in the range of 20% -29%;
the hot spot region refers to an image region with 1% -99% of KI67 positive cells in the image data.
2. The method according to claim 1, wherein the tumor in step 1) is breast cancer.
3. The method of claim 1, wherein the corresponding KI67 proliferation index in the hot spot region intercepted in step 3) comprises at least 1 of 5%, 10%, 15%, 20%, 30%, 40%, 50%, 60%, 70%, 80%.
4. The method of claim 3, wherein the hot spot region intercepted in step 3) has a corresponding KI67 proliferation index of 5%, 10%, 15%, 20%, 30%, 40%, 50%, 60%, 70%, 80%.
5. The method of any one of claims 1-4, further comprising printing the image obtained in step 3).
6. The standard comparison card for assisting in interpreting the proliferation index of KI67, prepared by the method of any one of claims 1-5.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010262409.6A CN111413504B (en) | 2020-04-03 | 2020-04-03 | Standard comparison card for assisting interpretation of KI67 proliferation index |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010262409.6A CN111413504B (en) | 2020-04-03 | 2020-04-03 | Standard comparison card for assisting interpretation of KI67 proliferation index |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN111413504A CN111413504A (en) | 2020-07-14 |
| CN111413504B true CN111413504B (en) | 2022-01-28 |
Family
ID=71491761
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010262409.6A Active CN111413504B (en) | 2020-04-03 | 2020-04-03 | Standard comparison card for assisting interpretation of KI67 proliferation index |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111413504B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113418920A (en) * | 2021-05-14 | 2021-09-21 | 广州金域医学检验中心有限公司 | Section staining quality interpretation method and device, computer equipment and storage medium |
Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1826529A (en) * | 2003-07-18 | 2006-08-30 | A&T株式会社 | Clinical examination analyzing device, clinical examination analyzing method, and program for allowing computer to execute the method |
| CN101799926A (en) * | 2010-05-05 | 2010-08-11 | 福州大学 | Automatically quantitative analysis system of Ki-67 immune-histochemical pathological image |
| CN102435728A (en) * | 2011-09-07 | 2012-05-02 | 福州大学 | Preparation method for positive control substance for inspection and control of quality in immunohistochemical process |
| CN103499694A (en) * | 2013-10-14 | 2014-01-08 | 中南大学 | Immunohistochemical kit for detecting colorectal cancer and malignancy degree thereof |
| CN106327508A (en) * | 2016-08-23 | 2017-01-11 | 马跃生 | Ki67 index automatic analysis method |
| CN107621542A (en) * | 2017-08-16 | 2018-01-23 | 上海芯超生物科技有限公司 | SABC slide with internal reference and its preparation method and application |
| CN109712142A (en) * | 2019-01-11 | 2019-05-03 | 山东省计算中心（国家超级计算济南中心） | Based on the isolated breast cancer Ki67/ER/PR caryochrome method of counting of dyeing |
| CN109872335A (en) * | 2019-02-28 | 2019-06-11 | 志诺维思（北京）基因科技有限公司 | A kind of automatic read tablet method and its system for PD-L1 antibody stained slice |
| CN110135221A (en) * | 2018-02-08 | 2019-08-16 | 佛山市水木联合医疗器械研究院 | A method of utilizing standard cell library image recognition sample cell |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5086476A (en) * | 1985-11-04 | 1992-02-04 | Cell Analysis Systems, Inc. | Method and apparatus for determining a proliferation index of a cell sample |
| EP0460071A4 (en) * | 1989-02-24 | 1993-02-03 | Cell Analysis Systems, Inc. | Method and apparatus for determining a proliferation index of a cell sample |
| JP5040597B2 (en) * | 2007-11-06 | 2012-10-03 | 日本電気株式会社 | Evaluation system, evaluation method, and evaluation program |
| JP6650453B2 (en) * | 2014-12-03 | 2020-02-19 | ベンタナ メディカル システムズ， インコーポレイテッド | Computational pathology system and method for early cancer prediction |
-
2020
- 2020-04-03 CN CN202010262409.6A patent/CN111413504B/en active Active
Patent Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1826529A (en) * | 2003-07-18 | 2006-08-30 | A&T株式会社 | Clinical examination analyzing device, clinical examination analyzing method, and program for allowing computer to execute the method |
| CN101799926A (en) * | 2010-05-05 | 2010-08-11 | 福州大学 | Automatically quantitative analysis system of Ki-67 immune-histochemical pathological image |
| CN102435728A (en) * | 2011-09-07 | 2012-05-02 | 福州大学 | Preparation method for positive control substance for inspection and control of quality in immunohistochemical process |
| CN103499694A (en) * | 2013-10-14 | 2014-01-08 | 中南大学 | Immunohistochemical kit for detecting colorectal cancer and malignancy degree thereof |
| CN106327508A (en) * | 2016-08-23 | 2017-01-11 | 马跃生 | Ki67 index automatic analysis method |
| CN107621542A (en) * | 2017-08-16 | 2018-01-23 | 上海芯超生物科技有限公司 | SABC slide with internal reference and its preparation method and application |
| CN110135221A (en) * | 2018-02-08 | 2019-08-16 | 佛山市水木联合医疗器械研究院 | A method of utilizing standard cell library image recognition sample cell |
| CN109712142A (en) * | 2019-01-11 | 2019-05-03 | 山东省计算中心（国家超级计算济南中心） | Based on the isolated breast cancer Ki67/ER/PR caryochrome method of counting of dyeing |
| CN109872335A (en) * | 2019-02-28 | 2019-06-11 | 志诺维思（北京）基因科技有限公司 | A kind of automatic read tablet method and its system for PD-L1 antibody stained slice |
Non-Patent Citations (4)
| Title |
|---|
| An interobserver reproducibility analysis of size-set semiautomatic counting for Ki67 assessment in breast cancer;Wang,Yi-xing等;《BREAST》;20191220;第49卷;第225-232页 * |
| Assessment of Ki67 in Breast Cancer: Recommendations from the International Ki67 in Breast Cancer Working Group;Dowsett,Mitch等;《JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE》;20111130;第103卷(第22期);第1656-1664页 * |
| Interobserver concordance of Ki67 labeling index in breast cancer: Japan Breast Cancer Research Group Ki67 Ring Study;Mikami,Yoshiki等;《CANCER SCIENCE》;20131130;第104卷(第11期);第1539-1543页 * |
| 同一观察者对乳腺癌Ki67免疫组化检测结果判读重复性研究;于鹤;《中国优秀博硕士学位论文全文数据库(硕士)医药卫生科技辑》;20190115(第01期);E072-2022 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN111413504A (en) | 2020-07-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7146886B2 (en) | Systems and methods for comprehensive multi-assay tissue analysis | |
| US7133547B2 (en) | Method for quantitative video-microscopy and associated system and computer software program product | |
| JP4504203B2 (en) | Scoring of estrogen and progesterone expressions based on image analysis | |
| CN109389584A (en) | Multiple dimensioned rhinopharyngeal neoplasm dividing method based on CNN | |
| ES2542106T3 (en) | Method for preparing quantitative videomicroscopy and associated system | |
| CN109815888B (en) | Novel Pasteur staining method-based abnormal cervical cell automatic identification method | |
| CN102881007B (en) | The image processing method of compound planar separation result and system thereof | |
| López et al. | Digital image analysis in breast cancer: an example of an automated methodology and the effects of image compression | |
| CN111413504B (en) | Standard comparison card for assisting interpretation of KI67 proliferation index | |
| CN113011257A (en) | Breast cancer immunohistochemical artificial intelligence interpretation method | |
| Colgan et al. | Reparative changes and the false-positive/false-negative Papanicolaou test: a study from the College of American Pathologists Interlaboratory Comparison Program in Cervicovaginal Cytology | |
| López et al. | Automated quantification of nuclear immunohistochemical markers with different complexity | |
| Razavi et al. | An automated and accurate methodology to assess ki-67 labeling index of immunohistochemical staining images of breast cancer tissues | |
| Priyankara et al. | An extensible computer vision application for blood cell recognition and analysis | |
| Choschzick et al. | Deep learning for the standardized classification of Ki-67 in vulva carcinoma: A feasibility study | |
| Nigam et al. | The International Academy of Cytology standardized reporting of breast fine-needle aspiration biopsy cytology: a 2 year’s retrospective study with application of categories and their assessment for risk of malignancy | |
| Roshan et al. | Accuracy of digital image analysis (DIA) of borderline human epidermal growth factor receptor (HER2) immunohistochemistry in invasive ductal carcinoma | |
| CN103592304A (en) | Stem object analysis system and stem object analysis method | |
| CN114739777A (en) | Quality control method and quality control product for immunohistochemical staining | |
| EP3563342A1 (en) | Automated system and method for creating and executing a scoring guide to assist in the analysis of tissue specimen | |
| US9122904B2 (en) | Method for optimization of quantitative video-microscopy and associated system | |
| Hammami | New Automated Quantitative Evaluation of Cancer Cell Proliferation with Ki-67 Method by Unsupervised Learning | |
| Chen et al. | A robust and automated cell counting method in quantification of digital breast cancer immunohistochemistry images | |
| Montironi et al. | Prostatic intraepithelial neoplasia: quantitation of the basal cell layer with machine vision system | |
| Rappai | A comparison of Ki67 index in carcinoma breast by digital image analysis with manual method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |